It also remains to be determined whether the standard first-line treatment of NSCLC harboring patients with a KRAS G12C mutation will continue to be immunotherapy (in the group showing PD-L1 expression ≥50%), or if it would make sense to explore a sotorasib-first strategy in future clinical trials. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.